Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Source: View publication →
In patients with severe eosinophilic asthma, intravenous mepolizumab significantly reduced the rate of clinically significant asthma exacerbations compared to placebo, establishing the clinical efficacy of IL-5 inhibition for this specific phenotype.
Key Findings
Study Design
Study Limitations
Clinical Significance
The DREAM trial was a landmark proof-of-concept and dose-ranging study that validated IL-5 as a critical therapeutic target for severe eosinophilic asthma. By demonstrating that mepolizumab halved the rate of severe exacerbations in patients with biomarker-proven eosinophilic inflammation, it shifted the paradigm of asthma management toward precision medicine. Although it did not show FEV1 or symptom improvements in this cohort, it successfully laid the clinical foundation for the approval and widespread use of anti-IL-5 biologics, sparing many patients from the morbidities of long-term systemic corticosteroids.
Historical Context
Historically, severe asthma was treated as a monolithic condition using escalating doses of inhaled and systemic corticosteroids. Early trials of anti-IL-5 therapies in unselected asthma populations failed to demonstrate clinical benefit. The DREAM trial resurrected anti-IL-5 therapy by utilizing a biomarker-driven approach, restricting enrollment specifically to patients with evidence of eosinophilic airway inflammation and a history of recurrent exacerbations. This successfully established the eosinophilic asthma endotype as a highly treatable trait.
Guided Discussion
High-yield insights from every perspective
Mepolizumab specifically targets Interleukin-5 (IL-5). What is the physiological role of IL-5 in the immune system, and why is targeting it highly effective in the specific phenotype of asthma studied in the DREAM trial?
Key Response
IL-5 is the primary cytokine produced by Th2 cells and Type 2 innate lymphoid cells (ILC2s) that is responsible for eosinophil production, maturation, activation, and survival in the bone marrow and tissues. By blocking IL-5, mepolizumab depletes circulating and airway eosinophils, directly halting the inflammatory cascade that drives exacerbations in eosinophilic asthma.
The DREAM trial selected patients with severe eosinophilic asthma. In your clinical practice, how do you define and identify this specific phenotype, and what practical biomarkers should be checked before initiating a biologic like mepolizumab?
Key Response
Eosinophilic asthma is characterized by an elevated absolute eosinophil count (typically >150-300 cells/mcL), elevated fractional exhaled nitric oxide (FeNO), and/or sputum eosinophils, usually in patients with severe exacerbations despite high-dose ICS/LABA therapy. In practice, a standard CBC with differential to check the absolute eosinophil count is the most accessible and critical initial biomarker to justify IL-5 inhibitor therapy.
The DREAM trial demonstrated a significant reduction in exacerbations, but notably, it did not show a clinically significant improvement in FEV1 or asthma daily symptom scores. How do you reconcile this disconnect pathophysiologically, and how does this affect your counseling when starting a patient on mepolizumab?
Key Response
IL-5 inhibition effectively prevents the acute eosinophilic spikes that drive severe acute exacerbations. However, it may not reverse fixed airway remodeling, smooth muscle hypertrophy, or non-eosinophilic pathways that drive daily symptoms or baseline bronchoconstriction. Patients must be counseled that the primary goal of mepolizumab is to prevent severe attacks and reduce oral corticosteroid burden, not necessarily to serve as a quick fix for daily shortness of breath.
The DREAM trial utilized intravenous mepolizumab, yet current clinical practice almost exclusively uses the subcutaneous formulation. How does the foundational data from the DREAM trial integrate with later studies (like MENSA) to support this transition, and what are the practice-management implications of using SC formulations?
Key Response
DREAM established the clinical efficacy and safety profile of IV mepolizumab across multiple doses, revealing a plateau in the dose-response curve that suggested lower doses could be effective. This laid the groundwork for the MENSA trial, which validated the 100 mg SC dose. For attendings, the shift to SC administration radically altered practice by enabling home administration, improving patient compliance and access, but requiring a shift in how clinicians monitor long-term adherence outside the infusion center.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The DREAM trial used a dose-ranging design (75 mg, 250 mg, and 750 mg IV) compared to placebo. From a methodological standpoint, how does splitting the active cohort into three dosage arms impact the statistical power for detecting rare adverse events, and what do the plateauing results suggest about the target's pharmacodynamics?
Key Response
Allocating a fixed overall sample size across multiple active arms reduces the N per arm, thereby decreasing the statistical power to detect rare, dose-dependent adverse events (inflating the risk of a Type II error for safety signals). The lack of superior clinical efficacy at 750 mg versus 75 mg suggests that systemic IL-5 receptor saturation, or maximal achievable eosinophil depletion, occurs at much lower systemic concentrations, which successfully guided subsequent lower-dose pharmaceutical development.
As a peer reviewer evaluating the DREAM trial, one might heavily scrutinize the inclusion criteria, which relied partly on historical exacerbation rates and fluctuating sputum eosinophils. How does the episodic nature of asthma introduce the risk of 'regression to the mean' in this trial, and how effectively does the placebo arm mitigate this threat to internal validity?
Key Response
Because asthma severity fluctuates, patients often enroll in trials following a peak in symptoms or exacerbations. Their subsequent exacerbation rates naturally decline, which is a classic 'regression to the mean'. While a robust, randomized, double-blind placebo arm theoretically controls for this because both groups should regress equally, a reviewer must verify that baseline peak eosinophil counts and historical exacerbations were perfectly balanced; any subtle asymmetry could artificially inflate the perceived treatment effect size.
Based on the evidence generated by the DREAM trial and subsequent supporting trials, how do current GINA (Global Initiative for Asthma) guidelines classify the strength of recommendation and level of evidence for mepolizumab, and where exactly does it fit in the stepwise treatment algorithm?
Key Response
GINA guidelines incorporate mepolizumab at Step 5. They provide a strong recommendation with Level A evidence for the use of anti-IL-5 biologics as add-on therapy in patients with severe, uncontrolled Type 2 (eosinophilic) asthma despite optimized high-dose ICS/LABA. The DREAM trial was instrumental in establishing this high level of evidence by demonstrating a definitive reduction in the rate of clinically significant exacerbations in this meticulously phenotyped population.
Clinical Landscape
Noteworthy Related Trials
MENSA Trial
Tested
Mepolizumab 75mg IV or 100mg SC every 4 weeks
Population
Patients with severe eosinophilic asthma and frequent exacerbations
Comparator
Placebo
Endpoint
Rate of clinically significant asthma exacerbations
SIROCCO Trial
Tested
Benralizumab 30mg SC every 4 or 8 weeks
Population
Patients with severe uncontrolled asthma and elevated blood eosinophils
Comparator
Placebo
Endpoint
Annual asthma exacerbation rate
LIBERTY ASTHMA QUEST Trial
Tested
Dupilumab 200mg or 300mg SC every 2 weeks
Population
Patients with uncontrolled moderate-to-severe asthma
Comparator
Placebo
Endpoint
Annualized rate of severe asthma exacerbations
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis